Although b-cryptoxanthin, a xanthophyll carotenoid, has been shown to exert an anabolic effect on bone calcification, little attention has been paid thus far to the precise mechanism of bone remodeling. Daily oral administration of b-cryptoxanthin significantly inhibited osteoclastic activation as well as reduction of bone volume in ovariectomized mice. In vitro studies revealed that b-cryptoxanthin inhibited differentiation and maturation of osteoclasts by repression of the nuclear factor-kB-dependent transcriptional pathway. Our results suggest that supplementation with b-cryptoxanthin would be beneficial for prophylaxis and for therapy of metabolic bone diseases associated with abnormal osteoclast activation. Bone homeostasis is complexly regulated by bone-resorbing osteoclasts and bone-forming osteoblasts (1). Osteoclasts are multinucleated cells derived from hematopoietic stem cells, whereas the osteoblast lineage is derived from primitive multipotent mesenchymal stem cells. Imbalance between regulation by osteoclasts and by osteoblasts results in certain metabolic bone diseases including osteoporosis (2).
Bone homeostasis is complexly regulated by bone-resorbing osteoclasts and bone-forming osteoblasts (1) . Osteoclasts are multinucleated cells derived from hematopoietic stem cells, whereas the osteoblast lineage is derived from primitive multipotent mesenchymal stem cells. Imbalance between regulation by osteoclasts and by osteoblasts results in certain metabolic bone diseases including osteoporosis (2) .
b-Cryptoxanthin, a major carotenoid routinely found in human serum, is primarily obtained from citrus fruits (3) . Several independent lines of evidence suggest a relationship between b-cryptoxanthin and pathophysiology (4) . b-cryptoxanthin alleviated diet-induces nonalcoholic steatohepatitis by suppressing inflammatory gene expression (5) . In addition, a high serum b-cryptoxanthin level is associated with a lower risk of lung cancer death (6) .
Moreover, serum b-cryptoxanthin is inversely associated with the risk of human osteoporosis (7) , and b-cryptoxanthin shows an anabolic effect on bone calcification in both in vitro and in vivo studies (8, 9) . Although several studies have been performed, the mechanisms of bone remodeling by b-cryptoxanthin remain unclear at the cellular and molecular levels. In the present study, we attempt to show a role and mechanisms of b-cryptoxanthin in the pathogenesis of bone diseases.
The protocol employed here meets the guidelines of the Japanese Society for Pharmacology and was approved by the Committee for Ethical Use of Experimental Animals at Kanazawa University. Eight-week-old female ddY mice were subjected to ovariectomy (OVX) or sham operation in aseptic environments, as described previously (10) . Ovariectomized mice received daily oral supplementation of b-cryptoxanthin freshly dissolved in drinking water at concentrations of 1 mg/L or 10 mg/L. Nonesterified b-cryptoxanthin for experiments was prepared and processed as described, and the purity of the b-cryptoxanthin obtained was 96% according to HPLC analysis (5) . No significant change was observed in the amount of daily intake of drinking water by mice, irrespective of the concentrations of b-cryptoxanthin used (data not shown). Mice were killed by decapitation 28 days after operation, followed by dissection of vertebrae and subsequent fixation with 10% formalin. Bone histomorphometric analyses were performed on vertebrae, as previously described (11) . In brief, the bone volume-to-tissue volume (BV/TV) ratio was measured by Von Kossa staining. Bone formation rate (BFR) was analyzed by calcein double-labeling. Mice were injected twice with calcein at a 3-day interval and were killed 2 days after the last injection. Osteoblast and osteoclast parameters were analyzed by staining with toluidine blue and with tartrateresistant acid phosphatase (TRAP), respectively. Analyses were performed with the Osteomeasure Analysis System (Osteometrics, Atlanta, GA), according to standard protocols. Preosteoclastic RAW264.7 cells were cultured with 20 ng/ml receptor activator of nuclear factor-kB (NF-kB) ligand (RANKL) (R&D systems, Minneapolis, MN, USA) for 4 consecutive days. TRAP staining, actin ring assay, pit formation assay, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay were performed, as previously described (12) . For the luciferase assay, cells were transfected with luciferase reporter vectors by the Lipofection method using Lipofectamine LTX/Plus reagent (Invitrogen, Carlsbad, CA, USA) followed by the preparation of cell lysates and determination of luciferase activity using specific substrates in a luminometer (ATTO Corp., Tokyo, Japan). Transfection efficiency was normalized to the activity of Renilla luc. Preosteoblastic MC3T3-E1 cells were cultured in the presence of differentiation cocktails (50 mg/ml ascorbic acid and 5 mm b-glycerophosphate). Determination of alkaline phosphatase (ALP) activity and Ca 2þ accumulation was done as indices of cellular differentiation and maturation, respectively. All results are expressed as mean ± standard error. Statistical significance was determined by two-tailed unpaired Student's t test or one-way analysis of variance with Bonferroni/Dunnett post hoc test.
We first administered b-cryptoxanthin orally in drinking water to ovariectomized mice for 28 consecutive days at concentrations of 1 mg/L and 10 mg/L. b-Cryptoxanthin administration did not affect body weight of mice, irrespective of OVX (Fig. 1A) . Although OVX markedly decreased uterine weight determined 28 days after operation, b-cryptoxanthin did not significantly affect the OVXinduced loss of uterine weight at the concentrations used (Fig. 1B) . Under these experimental conditions, a marked reduction was observed in cancellous bone stained by Von Kossa staining in vertebrae of ovariectomized mice compared with that in shamoperated mice (Fig. 1C) . However, in vertebrae of ovariectomized mice administered b-cryptoxanthin at 10 mg/L, a marked inhibition of loss of cancellous bone was observed (Fig. 1C) . Quantification of these data clearly revealed that supplementation with 10 mg/L bcryptoxanthin significantly suppressed the reduction of BV/TV ratio in cancellous bone of ovariectomized mice without affecting that in sham-operated mice (Fig. 1D) .
To define the cellular basis of the preventive effect of b-cryptoxanthin on bone loss, histomorphometric analyses of vertebrae were performed. In vertebrae of ovariectomized mice, significant increases were observed in the osteoclastic indices, extent of osteoclast surface/bone surface (Oc.S/BS; Fig. 2A and B) , and number of osteoclast/bone perimeter (N.Oc/B.Pm; Fig. 2A and C) and in the osteoblastic index, number of osteoblast/bone perimeter (N.Ob/B.Pm; Fig. 2D ). The administration of b-cryptoxanthin at 10 mg/L resulted in significant inhibition of the increases of Oc.S/BS and N.Oc/B.Pm to the level observed in sham-operated mice (Fig. 2AeC) but not of elevated N.Ob/B.Pm (Fig. 2D ). In addition, the administration of b-cryptoxanthin did not affect BFR, irrespective of OVX (Fig. 2E) . Moreover, b-cryptoxanthin at 10 mg/ L did not affect BFR of 8-week-old female mice (Fig. 2F) . According to the BV/TV ratios, b-cryptoxanthin could affect bone volume by prevention of osteoclastic activation rather than that of osteoblastic function. (Fig. 3A and B) , but it failed to affect MTT reduction as an index of cellular survival at the concentrations tested (Fig. 3C) . Sustained exposure to b-Cryptoxanthin led to the marked decrease in mRNA expression of osteoclastic marker genes, Cathepsin K (Ctsk) and Trap, in RAW264.7 cells (Fig. 3D) . Furthermore, b-cryptoxanthin significantly decreased the number of actin rings ( Fig. 3E and F) and area of pit formation (Fig. 3E and G 9, 14) , this is the first demonstration that b-cryptoxanthin prevents bone loss induced by ovariectomy by preferential disturbance of osteoclastic activation rather than by modulation of osteoblastic function. In this study, we employed 8-week-old ddY female mice for the OVX operation to replicate the in vivo experimental conditions often used previously (15) . Given that mice are considered to be still undergoing skeletal development at this age, this development could be one reason why b-cryptoxanthin did not significantly prevent the increase in osteoblast numbers with significant amelioration of the increased histomorphometric osteoclast parameters in ovariectomized mice. Indeed, as shown in Fig. 2F , bcryptoxanthin did not affect BFR of 8-week-old female mice.
Moreover, in our preliminary experiments, b-cryptoxanthin, at concentrations affecting osteoclastogenesis (1e20 mM), did not affect alkaline phosphatase activity or calcium accumulation in osteoblasts in vitro (Supplemental Fig. 1A and B) , suggesting that osteoblastogenesis cannot be directly regulated by b-cryptoxanthin in vitro and in vivo. The reason of paradoxical results with previous reports in terms of the anabolic function of b-cryptoxanthin could be at least in part accounted for by taking into consideration of the usage of different animals and cells, developmental stages of animals, or the purity and concentration of bcryptoxanthin. At any rate, we speculate that b-cryptoxanthin ameliorates the increased osteoclastic parameters through a mechanism relevant to predominant interference with the RANKL/NF-kB signaling pathway in osteoclasts, without affecting the increased osteoblastic indices, after estrogen deficiency in ovariectomized mice.
The reason why b-cryptoxanthin failed to significantly affect the bone mass in sham-operated mice in vivo but inhibited in vitro osteoclastogenesis is unclear. It may be that the in vitro analysis was performed on the differentiation and maturation of osteoclasts cultured with RANKL alone, in contrast to the in vivo situation in which other cells besides osteoclasts are present and a variety of cytokines other than RANKL are expressed in the bone. One possibility is that b-cryptoxanthin inhibits osteoclastic differentiation and maturation by preferential interference with signaling processes mediated by RANKL in osteoclasts. The present finding that b-cryptoxanthin significantly inhibited NF-kB-luc activity only in the presence of RANKL in pre-osteoclastic RAW264.7 cells gives support to this idea.
Long-term intake of b-cryptoxanthin-rich foods gradually increases blood b-cryptoxanthin levels in humans and animals (4).
On the basis of the present findings, we accordingly propose that appropriate consumption of b-cryptoxanthin-rich foods such as Satsuma mandarin (Citrus unshiu Marc.) would be beneficial for the maintenance of bone health and prophylaxis of menopausal osteoporosis, by a mechanism relevant to the inhibition of boneresorbing osteoclast activation.
